Arpana Agrawal1, Michael T Lynskey2, Kathleen K Bucholz3, Manav Kapoor3, Laura Almasy4, Danielle M Dick5, Howard J Edenberg6, Tatiana Foroud6, Alison Goate3, Dana B Hancock7, Sarah Hartz3, Eric O Johnson7, Victor Hesselbrock8, John R Kramer9, Samuel Kuperman10, John I Nurnberger6, Marc Schuckit11, Laura J Bierut3. 1. Washington University School of Medicine, Department of Psychiatry, St. Louis, MO, USA. Electronic address: arpana@wustl.edu. 2. Washington University School of Medicine, Department of Psychiatry, St. Louis, MO, USA; King's College, Institute of Psychiatry, London, UK. 3. Washington University School of Medicine, Department of Psychiatry, St. Louis, MO, USA. 4. Texas Biomedical Research Institute, San Antonio, TX, USA. 5. Virginia Commonwealth University, Virginia Institute of Psychiatric and Behavioral Genetics, VA, USA. 6. Indiana University School of Medicine, Indianapolis, IN, USA. 7. RTI International, Behavioral and Health Epidemiology Program, Research Triangle Park, NC, USA. 8. University of Connecticut, Department of Psychiatry, Farmington, CT, USA. 9. University of Iowa School of Medicine, Department of Psychiatry, Iowa City, IA, USA. 10. University of Iowa Hospitals, Division of Child Psychiatry, Iowa City, IA, USA. 11. University of California at San Diego, Department of Psychiatry, San Diego, CA, USA.
Abstract
BACKGROUND: We explore the factor structure of DSM-5 cannabis use disorders, examine its prevalence across European- and African-American respondents as well as its genetic underpinnings, utilizing data from a genome-wide study of single nucleotide polymorphisms (SNPs). We also estimate the heritability of DSM-5 cannabis use disorders explained by these common SNPs. METHODS: Data on 3053 subjects reporting a lifetime history of cannabis use were utilized. Exploratory and confirmatory factor analyses were conducted to create a factor score, which was used in a genome-wide association analysis. p-values from the single SNP analysis were examined for evidence of gene-based association. The aggregate effect of all SNPs was also estimated using Genome-Wide Complex Traits Analysis. RESULTS: The unidimensionality of DSM-5 cannabis use disorder criteria was demonstrated. Comparing DSM-IV to DSM-5, a decrease in prevalence of cannabis use disorders was only noted in European-American respondents and was exceedingly modest. For the DSM-5 cannabis use disorders factor score, no SNP surpassed the genome-wide significance testing threshold. However, in the European-American subsample, gene-based association testing resulted in significant associations in 3 genes (C17orf58, BPTF and PPM1D) on chromosome 17q24. In aggregate, 21% of the variance in DSM-5 cannabis use disorders was explained by the genome-wide SNPs; however, this estimate was not statistically significant. CONCLUSIONS: DSM-5 cannabis use disorder represents a unidimensional construct, the prevalence of which is only modestly elevated above the DSM-IV version. Considerably larger sample sizes will be required to identify individual SNPs associated with cannabis use disorders and unequivocally establish its polygenic underpinnings.
BACKGROUND: We explore the factor structure of DSM-5 cannabis use disorders, examine its prevalence across European- and African-American respondents as well as its genetic underpinnings, utilizing data from a genome-wide study of single nucleotide polymorphisms (SNPs). We also estimate the heritability of DSM-5 cannabis use disorders explained by these common SNPs. METHODS: Data on 3053 subjects reporting a lifetime history of cannabis use were utilized. Exploratory and confirmatory factor analyses were conducted to create a factor score, which was used in a genome-wide association analysis. p-values from the single SNP analysis were examined for evidence of gene-based association. The aggregate effect of all SNPs was also estimated using Genome-Wide Complex Traits Analysis. RESULTS: The unidimensionality of DSM-5 cannabis use disorder criteria was demonstrated. Comparing DSM-IV to DSM-5, a decrease in prevalence of cannabis use disorders was only noted in European-American respondents and was exceedingly modest. For the DSM-5 cannabis use disorders factor score, no SNP surpassed the genome-wide significance testing threshold. However, in the European-American subsample, gene-based association testing resulted in significant associations in 3 genes (C17orf58, BPTF and PPM1D) on chromosome 17q24. In aggregate, 21% of the variance in DSM-5 cannabis use disorders was explained by the genome-wide SNPs; however, this estimate was not statistically significant. CONCLUSIONS: DSM-5 cannabis use disorder represents a unidimensional construct, the prevalence of which is only modestly elevated above the DSM-IV version. Considerably larger sample sizes will be required to identify individual SNPs associated with cannabis use disorders and unequivocally establish its polygenic underpinnings.
Authors: James W Langenbucher; Erich Labouvie; Christopher S Martin; Pilar M Sanjuan; Lawrence Bavly; Levent Kirisci; Tammy Chung Journal: J Abnorm Psychol Date: 2004-02
Authors: T Reich; H J Edenberg; A Goate; J T Williams; J P Rice; P Van Eerdewegh; T Foroud; V Hesselbrock; M A Schuckit; K Bucholz; B Porjesz; T K Li; P M Conneally; J I Nurnberger; J A Tischfield; R R Crowe; C R Cloninger; W Wu; S Shears; K Carr; C Crose; C Willig; H Begleiter Journal: Am J Med Genet Date: 1998-05-08
Authors: Li-Tzy Wu; George E Woody; Chongming Yang; Jeng-Jong Pan; Bryce B Reeve; Dan G Blazer Journal: Int J Methods Psychiatr Res Date: 2012-02-20 Impact factor: 4.035
Authors: S Hong Lee; Teresa R DeCandia; Stephan Ripke; Jian Yang; Patrick F Sullivan; Michael E Goddard; Matthew C Keller; Peter M Visscher; Naomi R Wray Journal: Nat Genet Date: 2012-02-19 Impact factor: 38.330
Authors: Eric O Johnson; Dana B Hancock; Joshua L Levy; Nathan C Gaddis; Grier P Page; Cristie Glasheen; Nancy L Saccone; Laura J Bierut; Alex H Kral Journal: Addict Biol Date: 2015-07-23 Impact factor: 4.280
Authors: James R Ashenhurst; K Paige Harden; Travis T Mallard; William R Corbin; Kim Fromme Journal: J Stud Alcohol Drugs Date: 2017-09 Impact factor: 2.582
Authors: Caitlin E Carey; Arpana Agrawal; Bo Zhang; Emily D Conley; Louisa Degenhardt; Andrew C Heath; Daofeng Li; Michael T Lynskey; Nicholas G Martin; Grant W Montgomery; Ting Wang; Laura J Bierut; Ahmad R Hariri; Elliot C Nelson; Ryan Bogdan Journal: J Abnorm Psychol Date: 2015-11